GlassScriptPhysician profile
Robert P Shavelson
NPI 1730173584
$5,736.34
in general payments reported to CMS, 2019-2025
30 companies · $783 in 2025
The $783 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $744 · 2021: $904 · 2022: $620 · 2023: $785 · 2024: $971 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,480 · Education: $32.97 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,479.98 |
| Education | $32.97 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,244.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $761.12 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $583.94 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $558.42 | 2019-2025 | Jardiance |
| Pfizer INC. | $412.21 | 2019-2024 | |
| Abbvie INC. | $287.83 | 2021-2025 | Qulipta |
| Lilly USA, LLC | $235.31 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Amarin Pharma, INC. | $189.78 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $185.90 | 2022-2025 | Quviviq, Quviviq |
| Amgen INC. | $185.27 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $136.47 | 2022-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $127.88 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.22 | 2019-2022 | |
| Exact Sciences Corporation | $87.40 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $84.06 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $75.34 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.44 | 2021-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $64.70 | 2019-2021 | |
| Astellas Pharma US INC | $55.36 | 2019-2025 | Veozah |
| Horizon Therapeutics Plc | $52.47 | 2022 | |
| Millicent US INC | $47.75 | 2024 | Femring, Intrarosa |
| Sanofi Pasteur INC. | $41.19 | 2023 | |
| Medicure Pharma INC. | $40.23 | 2024-2025 | Zypitamag |
| Allergan, INC. | $23.10 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $20.04 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $16.09 | 2025 | Evkeeza |
| Janssen Pharmaceuticals, INC | $15.40 | 2020 | |
| Daiichi Sankyo INC. | $14.67 | 2022 | |
| Dexcom, INC. | $14.47 | 2025 | Dexcom G6 Transmitter |
| Eisai INC. | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Shavelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.